Anti-PD-L1 antibody and use thereof
AssigneeOricell Therapeutics Co., Ltd.
InventorsBohua Li, Huajing Wang, Xiaowen He
Life of this patent
Estimating the term…
Abstract
An antibody that binds to the PD-L1 protein or CD137 protein, an antigen-binding fragment or a variant thereof, as well as a bispecific antibody that can bind to both the PD-L1 protein and the CD137 protein. The bispecific antibody has a strong ability to specifically recognize the PD-L1 protein and the CD137 protein, and can enhance T-cell activity. The antibody or the antigen-binding fragment or the variant thereof and the bispecific antibody may be used in the prevention and treatment of tumors.
Claims18
An antibody or an antigen binding fragment thereof capable of binding to PD-L1 protein, comprising a light chain variable region VL which comprises LCDRI-3 and a heavy chain variable region VH which comprises HCDRI-3, wherein said antibody or antigen binding fragment thereof comprises amino acid sequences selected from any one of the following groups:
- (a) LCDR1:
- SEQ ID NO:54, LCDR2:
- SEQ ID NO:60, LCDR3:
- SEQ ID NO:63, HCDR1:
- SEQ ID NO:46, HCDR2:
- SEQ ID NO:48 and HCDR3:
- SEQ ID NO:50;
- (b) LCDR1:
- SEQ ID NO:55, LCDR2:
- SEQ ID NO:60, LCDR3:
- SEQ ID NO:64, HCDR1:
- SEQ ID NO:47, HCDR2:
- SEQ ID NO:48 and HCDR3:
- SEQ ID NO:
- 51;
- (c) LCDR1:
- SEQ ID NO:55, LCDR2:
- SEQ ID NO:60, LCDR3:
- SEQ ID NO:64, HCDR1:
- SEQ ID NO:47, HCDR2:
- SEQ ID NO:48 and HCDR3:
- SEQ ID NO:52;
- (d) LCDRI:
- SEQ ID NO:56, LCDR2:
- SEQ ID NO:61, LCDR3:
- SEQ ID NO:64, HCDR1:
- SEQ ID NO:47, HCDR2:
- SEQ ID NO:48 and HCDR3:
- SEQ ID NO:52;
- (e) LCDRI:
- SEQ ID NO:57, LCDR2:
- SEQ ID NO:61, LCDR3:
- SEQ ID NO:64, HCDRI:
- SEQ ID NO:47, HCDR2:
- SEQ ID NO:48 and HCDR3:
- SEQ ID NO:52;
- and
- (f) LCDR1:
- SEQ ID NO:58, LCDR2:
- SEQ ID NO:61, LCDR3:
- SEQ ID NO:64, HCDRI:
- SEQ ID NO:47, HCDR2:
- SEQ ID NO:48 and HCDR3:
- SEQ ID NO:52.
Dependencies are inferred from the claim text.